Valuation: Positron Corporation

Market Cap 57.87M 50.29M 46.9M 43.1M 81.29M 5.52B 82.7M 553M 217M 2.75B 217M 213M 9.11B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 56.74M 49.31M 45.98M 42.25M 79.69M 5.41B 81.08M 542M 212M 2.7B 213M 208M 8.93B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
47.44%
Yield 2024 *
-
Yield 2025 -
1 day-8.20%
1 week-3.72%
Current month-8.20%
1 month-13.04%
3 months-11.61%
6 months-11.13%
Current year-3.14%
1 week 1.53
Extreme 1.53
1.85
1 month 1.43
Extreme 1.43
1.85
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 26/02/2018
Sales & Marketing - 23/06/2022
Corporate Officer/Principal 40 24/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-8.20%-3.72%-7.41%+23.47% 57.87M
+0.81%+6.09%-12.65%-15.02% 14.02B
-1.55%-8.26%+36.41%-10.26% 3.9B
+1.38%+13.25%-35.47%-53.29% 1.27B
+6.00%+16.59%-32.01%-39.45% 1.18B
+0.77%-3.10%+38.37%+109.38% 1.16B
+0.80%+6.47%-44.99% - 952M
-9.05%+0.89%+17.46%+85.35% 500M
+8.97%+10.48%+83.38% - 329M
-1.03%+0.97%-59.68%+218.60% 265M
Average -0.11%+2.82%-1.66%+39.85% 2.36B
Weighted average by Cap. +0.57%+3.33%-4.09%-6.08%

Financials

2024 2025
Net sales 588K 511K 476K 438K 825K 56M 840K 5.61M 2.2M 27.92M 2.21M 2.16M 92.45M 461K 401K 374K 344K 648K 43.99M 659K 4.41M 1.73M 21.93M 1.73M 1.69M 72.61M
Net income -2.38M -2.07M -1.93M -1.77M -3.34M -227M -3.4M -22.72M -8.9M -113M -8.93M -8.74M -374M -10.6M -9.21M -8.59M -7.9M -14.89M -1.01B -15.15M -101M -39.68M -504M -39.82M -38.95M -1.67B
Net Debt 1.42M 1.24M 1.15M 1.06M 2M 136M 2.04M 13.6M 5.33M 67.7M 5.35M 5.23M 224M -1.14M -987K -921K -846K -1.6M -108M -1.62M -10.85M -4.25M -54M -4.27M -4.17M -179M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
03/08/26 US$1.618 -8.20% 28,110
31/07/26 US$1.762 +5.51% 12,986
30/07/26 US$1.670 0.00% 1,890
29/07/26 US$1.670 +4.31% 733
28/07/26 US$1.601 +1.97% 130
  1. Stock Market
  2. Stocks
  3. POSC Stock